574 related articles for article (PubMed ID: 33667951)
1. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
Sarkar E; Khan A
Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer.
Khan A; Sarkar E
Cancer Treat Res Commun; 2022; 33():100641. PubMed ID: 36193597
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
5. Gene editing and CRISPR in the clinic: current and future perspectives.
Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
[TBL] [Abstract][Full Text] [Related]
7. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy to get on point with base editing.
Harbottle JA
Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
[TBL] [Abstract][Full Text] [Related]
9. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
11. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
12. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials.
Khalaf K; Janowicz K; Dyszkiewicz-Konwińska M; Hutchings G; Dompe C; Moncrieff L; Jankowski M; Machnik M; Oleksiewicz U; Kocherova I; Petitte J; Mozdziak P; Shibli JA; Iżycki D; Józkowiak M; Piotrowska-Kempisty H; Skowroński MT; Antosik P; Kempisty B
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32796761
[TBL] [Abstract][Full Text] [Related]
14. Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.
Pavlovic K; Carmona-Luque M; Corsi GI; Maldonado-Pérez N; Molina-Estevez FJ; Peralbo-Santaella E; Cortijo-Gutiérrez M; Justicia-Lirio P; Tristán-Manzano M; Ronco-Díaz V; Ballesteros-Ribelles A; Millán-López A; Heredia-Velázquez P; Fuster-García C; Cathomen T; Seemann SE; Gorodkin J; Martin F; Herrera C; Benabdellah K
Front Immunol; 2024; 15():1401683. PubMed ID: 38868778
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
[TBL] [Abstract][Full Text] [Related]
16. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
17. A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment.
Yang X; Zhang B
Funct Integr Genomics; 2023 May; 23(2):182. PubMed ID: 37231285
[TBL] [Abstract][Full Text] [Related]
18. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y; Xue J; Deng T; Zhou X; Yu K; Deng L; Huang M; Yi X; Liang M; Wang Y; Shen H; Tong R; Wang W; Li L; Song J; Li J; Su X; Ding Z; Gong Y; Zhu J; Wang Y; Zou B; Zhang Y; Li Y; Zhou L; Liu Y; Yu M; Wang Y; Zhang X; Yin L; Xia X; Zeng Y; Zhou Q; Ying B; Chen C; Wei Y; Li W; Mok T
Nat Med; 2020 May; 26(5):732-740. PubMed ID: 32341578
[TBL] [Abstract][Full Text] [Related]
19. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
Wellhausen N; Agarwal S; Rommel PC; Gill SI; June CH
Curr Opin Immunol; 2022 Feb; 74():76-84. PubMed ID: 34798542
[TBL] [Abstract][Full Text] [Related]
20. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
